Stevens-Johnson induced by imiquimod 5% cream: a case report
https://doi.org/10.4081/dr.2024.9930
Accepted: 6 February 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. Severe systemic side effects associated to imiquimod 5% cream are rare, although few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated to topical treatment with imiquimod of two superficial basal cell carcinomas.
Cantisani C, Lazic T, Richetta AG, Clerico R, Mattozzi C, Calvieri S. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat Inflamm Allergy Drug Discov. 2012 Jan;6:65-9. DOI: https://doi.org/10.2174/187221312798889301
Nanda J, Bermudez R. Imiquimod. 2022 Jul 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
Camacho Molina A, Alarcón Manoja E, Corzo Gilabert JR, García Gil D. Erythema multiforme induced by topical imiquimod. Emergencias. 2020;32:219.
Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28;57(9):895. doi: 10.3390/medicina57090895. PMID: 34577817; PMCID: PMC8472007. DOI: https://doi.org/10.3390/medicina57090895
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6. DOI: https://doi.org/10.1001/archderm.129.1.92
Shaw B, Madden M, Crespo A, Madruga M, Carlan SJ. A Rare Case of Severe Stevens-Johnson Syndrome Triggered by Topical Ofloxacin. Am J Case Rep. 2023 Nov 12;24:e941992. doi: 10.12659/AJCR.941992. PMID: 37952083; PMCID: PMC10654684. DOI: https://doi.org/10.12659/AJCR.941992
Das A, Banerjee A, Tripathy K. Topical moxifloxacin-induced Stevens-Johnson syndrome. J Cataract Refract Surg. 2017 Jun;43(6):860-861. doi: 10.1016/j.jcrs.2017.03.043. PMID: 28732631. DOI: https://doi.org/10.1016/j.jcrs.2017.03.043
Núñez Ortiz A, Trigo Salado C, de la Cruz Ramírez MD, Herrera Justiniano JM, Leo Carnerero E. Topical mesalazine as a cause of Stevens-Johnson syndrome. Rev Esp Enferm Dig. 2018 Nov;110(11):736-738. doi: 10.17235/reed.2018.5429/2017. PMID: 29931986. DOI: https://doi.org/10.17235/reed.2018.5429/2017
Leitner C. Topical imiquimod—Be aware of the unexpected. JAAD. 2016;74:AB223. DOI: https://doi.org/10.1016/j.jaad.2016.02.877
Tedman A, Malla U, Vasanthakumar L, Buzacott K, Banney L. Stevens-Johnson syndrome due to topical imiquimod 5%. Aust J Gen Pract. 2020;49:662-664. DOI: https://doi.org/10.31128/AJGP-11-19-5145
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
